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In this issue of Familial Cancer, Barnes et al. describe a 
screening program for individuals at high risk of develop-
ing pancreatic ductal adenocarcinoma (PDAC) [1]. Approxi-
mately 3–10% of all patients with PDAC have a positive 
family history for this cancer [2], and 4% have an underlying 
gene defect, with ATM, BRCA1 & BRCA2, and PALB2 being 
the most commonly effected genes [3–6] (Table 1). Famil-
ial pancreatic cancer (FPC) is defined by the occurrence of 
PDAC in two or more first-degree relatives, in the absence of 
an underlying gene defect [2]. The risk of developing PDAC 
depends on the particular gene defect (Table 1) [7–12], and 
in FPC, on the number of first-degree family members with 
PDAC.
Since the first report of pancreatic screening of high-risk 
individuals by Brentnall et al., several other screening stud-
ies have been completed [13]. Most studies involved FPC 
families, while a few included carriers of a PDAC-associated 
gene defect [12, 14–16]. The screening protocols used in 
these studies varied widely, including MRI only, both MRI 
and endoscopic ultrasound (EUS), or MRI with optional 
EUS.
Barnes et al. are to be commended on the development of 
a solid and well-structured clinical program [1]. Adopting a 
multidisciplinary approach, the program uses gene panels, 
appropriate genetic counseling, and a protocol that includes 
annual 3.0 T MRI and additional EUS in case of abnormali-
ties. All results are discussed at a multidisciplinary PDAC 
conference. Five years into the program, a total of 75 indi-
viduals have participated, including 42 (56%) carriers of 
a PDAC-associated gene defect and 35 (44%) individuals 
with FPC. One cholangiocarcinoma was detected and cystic 
lesions were observed in 40% of cases, which is in agree-
ment with previous studies.
At a consensus meeting of the International CAPS (Can-
cer of the Pancreas Screening) consortium in 2013 [17], 
detailed criteria were developed for the selection of indi-
viduals eligible for screening of the pancreas. In general, 
a lifetime risk of 5% or more was considered an indication 
for screening. Publication of the guidelines has increased 
interest in these high-risk groups and enhanced the imple-
mentation of screening worldwide. However, an important 
remaining issue is that the value of the proposed screen-
ing programs has not yet been proven. These programs are 
therefore only suitable in a research setting and in special-
ized centers with high-volume pancreatic surgery and well-
defined screening protocols. The protocol developed by 
Barnes et al. is a good example of a high-quality program 
[1].
The choice for (3.0 T) MRI as the primary screening tool, 
followed by EUS in case of abnormalities, seems appropri-
ate, although the optimal screening approach still needs to 
be defined. A study by Harinck et al. showed that the results 
of MRI and EUS are complementary, MRI showing greater 
sensitivity in the identification of cystic lesions and EUS in 
the detection of solid lesions [18]. The program described by 
Barnes and colleagues also included the use of tumor mark-
ers (CEA, CA19.9). Although both markers have proven 
value in the follow-up of various cancers after treatment, the 
value of these markers for screening purposes is unknown. 
One major drawback is that when elevated levels of a marker 
are identified without evidence of abnormalities, as reported 
in a few cases in this study, severe anxiety may result. The 
possibility of false positive findings should therefore be dis-
cussed with patients beforehand.
Another major question is which individuals to screen? 
Pandharipande et al. developed a simulation model for 
PDAC that can be used to evaluate the effect of screen-
ing of specific high-risk groups [19]. Using this model, 
they showed an increased life expectancy for individu-
als with a BRCA1/BRCA2 mutation and a strong family 
history for PDAC. In contrast, in the overall cohort of 
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BRCA1/BRCA2 carriers with and without a family history 
of PDAC, life expectancy was reduced. This was attributed 
to the increased discovery of insignificant lesions and sub-
sequent surgical intervention. The authors concluded that 
only those individuals with a sufficiently increased risk 
may derive benefit from screening.
In view of this conclusion, it is important to recog-
nize that the risk of developing PDAC for most groups 
of mutation carriers, including those in the Barnes’s 
study, is still unknown (Table 1). A recent study on the 
frequency and type of gene defects in a large series of spo-
radic PDAC reported that family history is inconclusive in 
most patients with an identified gene defect [3] Based on 
this observation, the authors concluded that routine gene 
testing of patients with newly diagnosed pancreatic cancer 
may yield significant clinical benefits for patients and fam-
ily members. On the other hand, this approach may lead to 
identification of many individuals with an unknown risk of 
PDAC and may thus cause considerable anxiety, especially 
in view of the unproven value of screening. Implementa-
tion of routine testing of gene panels in sporadic PDAC 
may therefore require further consideration.
The prognosis of PDAC is still very poor, and has seen 
no improvement over the last 50 years. The only path to 
a better prognosis is early detection of precursor lesions 
or early stage cancer, particularly by offering screening 
to individuals at high risk. Despite the many difficulties 
involved in the screening of these high-risk groups, if we 
wish to make progress we should continue screening but 
under strict preconditions. The first step is the develop-
ment of an appropriate, well-structured surveillance pro-
gram as presented by Barnes et al. in this issue.
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